Article
Oncology
Yinghan Su, Changqing Su, Lunxiu Qin
Summary: Oncolytic virotherapy has become an important strategy in cancer immunotherapy by reshaping the tumor microenvironment and inducing an antitumor immune response. The combination therapy of oncolytic viruses and immunotherapy has shown promising results in preclinical and clinical studies.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Seyed-Mahmood Seyed-Khorrami, Arezou Azadi, Nasrin Rastegarvand, Ala Habibian, Hoorieh Soleimanjahi, Marek J. Los
Summary: Immunotherapy and virotherapy have emerged as new methods for cancer treatment, with better specificity and outcomes. Applying these strategies in the treatment of malignancies is of great significance, based on advances in understanding cancer cell biology and oncolytic viruses.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Caroline P. Kerr, Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert, Zachary S. Morris
Summary: Targeted radionuclide therapy (TRT) and immunotherapy are growing rapidly in cancer treatments, and their combinations are being investigated in research and clinical trials. TRT has the advantage of treating disease sites selectively with intravenous injection, making it beneficial in metastatic disease settings. Preclinical studies have shown the potential of combining radiation therapy with immune checkpoint blockade to treat metastases, but clinical studies have shown mixed results. Despite the interest in translating TRT and immunotherapy combinations, there are still many unanswered questions regarding the mechanisms and optimal implementation. This review highlights the current research and clinical trials investigating the interactions between anti-tumor immunity, radiation therapy, and the combinations with TRT and immunotherapies.
Review
Cell Biology
Hadi Esmaeili Gouvarchin Ghaleh, Gazal Vakilzadeh, Ali Zahiri, Mahdieh Farzanehpour
Summary: Mesenchymal stem cells (MSCs) have the unique ability to migrate to tumors, which makes them an excellent candidate for targeted delivery of oncolytic viruses (OVs) to treat cancer. OVs selectively infect and destroy tumor cells while sparing normal cells, and they can induce immunogenic cell death and contain curative transgenes. When combined with MSCs, OVs can modulate the tumor microenvironment and trigger anti-tumor immune responses, offering a promising approach for cancer treatment.
CELL COMMUNICATION AND SIGNALING
(2023)
Review
Pharmacology & Pharmacy
Richard Kolade Omole, Oluwaseyi Oluwatola, Millicent Tambari Akere, Joseph Eniafe, Elizabeth Oladoyin Agboluaje, Oluwafemi Bamidele Daramola, Yemisi Juliet Ayantunji, Temiloluwa Ifeoluwa Omotade, Nkem Torimiro, Modupe Stella Ayilara, Oluwole Isaac Adeyemi, Olubusola Sajanat Salinsile
Summary: The worldwide burden of cancers is increasing rapidly, and conventional treatment methods have limitations. Oncolytic viruses provide a new immunotherapeutic option that can target cancer cells and spare normal cells. This review investigates the severity of the global and sub-Saharan African cancer burden, discusses the mechanisms of action of oncolytic viruses, and explores their application in cancer treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Immunology
Guillaume St-Cyr, Daphne Penarroya, Lauren Daniel, Hugo Giguere, Almohanad A. A. Alkayyal, Lee-Hwa Tai
Summary: MiRNAs play important roles in the tumor microenvironment by silencing gene expression. They are dysregulated in cancer and have become attractive therapeutic targets. MiRNAs can improve oncolytic viruses by enhancing viral oncolysis, tumor suppression, and immune modulation. On the other hand, oncolytic viruses can overcome the limitations of miRNA-based therapies by delivering therapeutic payloads directly into the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Yi Ren, Jia-Meng Miao, Yuan-Yuan Wang, Zheng Fan, Xian-Bin Kong, Long Yang, Gong Cheng
Summary: Immunotherapy is promising in oncology, immune checkpoint inhibitors alone may not be effective for pMMR/MSS/MSI-L mCRC, the combination with oncolytic viruses shows exciting results in treating tumors by modulating the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Rui Rui, Liqun Zhou, Shiming He
Summary: Immunotherapy has revolutionized cancer treatment, with ongoing advancements. The aim of cancer immunotherapy is to activate the host immune system to fight against malignant tumors. Tumor infiltrating leukocytes play a role in tumor microenvironment and their interaction with tumor cells influences tumor progression. Various immunotherapies, such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer, have shown promising efficacy. This review summarizes the recent research progress in tumor immunotherapy, including molecular mechanisms, clinical effects, and limitations.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Lihong Wang, Louisa S. Chard Dunmall, Zhenguo Cheng, Yaohe Wang
Summary: Tumor cells manipulate the local environment to create a tumor microenvironment (TME) that promotes tumor survival and metastasis. Oncolytic viruses (OVs) are a promising therapeutic approach that can modify the TME to activate antitumor immune cells and overcome tumor therapeutic resistance and recurrence. This review discusses the tropism of OVs towards tumor cells and their interaction with immune cells, tumor stroma, vasculature, and the metabolic environment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Ling Zhang, Seyed Abbas Pakmehr, Reza Shahhosseini, Maryam Hariri, Azadeh Fakhrioliaei, Farid Karkon Shayan, Wenxue Xiang, Sepideh Karkon Shayan
Summary: The immunosuppressive tumor microenvironment (TME) hinders the effectiveness of ICIs and CAR T-cell therapy in solid tumor treatment. Oncolytic virotherapy (OV) shows potential in reprogramming TME and improving the therapeutic outcomes of solid tumors.
Review
Immunology
Ruchi Roy, Sunil Kumar Singh, Sweta Misra
Summary: This article discusses the involvement of the immune system in biological therapies targeting tumor microenvironment. It highlights the significant advancements in utilizing immune cells, particularly T cells, for the treatment of malignant tumors. The article also covers therapeutic approaches and developmental strategies to treat cancer.
Review
Oncology
Bin Zhang, Xilei Wang, Ping Cheng
Summary: Oncolytic viruses have unique therapeutic mechanisms, including direct oncolysis and induction of antitumor immunity. They can be genetically engineered to remodel the tumor immune microenvironment and enhance antitumor efficacy. Additionally, they can serve as vectors for delivering immunomodulatory cytokines or antibodies.
FRONTIERS IN ONCOLOGY
(2021)
Review
Virology
Yogesh R. Suryawanshi, Autumn J. Schulze
Summary: Glioblastoma is a challenging tumor type to treat with conventional therapy, but immunotherapeutic agents have shown limited success and further optimization is needed. Some oncolytic viruses have demonstrated the ability to infect tumors in malignant glioma patients, but hurdles like the blood-brain barrier and tumor heterogeneity can reduce their efficacy. Strategies are being developed to optimize oncolytic virotherapy outcomes.
Article
Virology
Xinyue Deng, Yinan Shen, Ming Yi, Chaomei Zhang, Bin Zhao, Guansheng Zhong, Dixuan WeiyangLou, Dixuan Xue, Qi Leng, Jun Ding, Ronghua Zhao, Weiguo Jia, Chenfang Dong, Zhijun Dai
Summary: New strategies are needed to improve the treatment of breast cancer. VG161, a novel replicable recombinant oncolytic herpes simplex virus, has shown antitumor effects in various cancers. This study demonstrates that combination therapy with VG161 and paclitaxel effectively inhibits breast cancer growth and elicits a robust antitumor immune response.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Oncology
Xin-Ying Tang, Yu-Shi Ding, Tao Zhou, Xu Wang, Yong Yang
Summary: CAR-T cell therapy has shown promising results in hematologic malignancies, but its efficacy in solid tumors is limited due to antigen heterogeneity, suboptimal trafficking, and immunosuppressive microenvironment. Combination with oncolytic viruses (OV) might be a novel solution to overcome these challenges and improve the therapeutic outcomes for non-hematologic malignancies.
Article
Oncology
Rozanne Arulanandam, Cory Batenchuk, Fernando A. Angarita, Kathryn Ottolino-Perry, Sophie Cousineau, Amelia Mottashed, Emma Burgess, Theresa J. Falls, Naomi De Silva, Jovian Tsang, Grant A. Howe, Marie-Claude Bourgeois-Daigneault, David P. Conrad, Manijeh Daneshmand, Caroline J. Breitbach, David H. Kim, Leda Raptis, Subash Sad, Harold Atkins, Michael S. Huh, Jean-Simon Diallo, Brian D. Lichty, Carolina S. Ilkow, Fabrice Le Boeuf, Christina L. Addison, J. Andrea McCart, John C. Bell
Article
Biotechnology & Applied Microbiology
Laura Evgin, Sergio A. Acuna, Christiano Tanese de Souza, Monique Marguerie, Chantal G. Lemay, Carolina S. Ilkow, C. Scott Findlay, Theresa Falls, Kelley A. Parato, David Hanwell, Alyssa Goldstein, Roberto Lopez, Sandra Lafrance, Caroline J. Breitbach, David Kirn, Harold Atkins, Rebecca C. Auer, Joshua M. Thurman, Gregory L. Stahl, John D. Lambris, John C. Bell, J. Andrea McCart
Article
Biochemistry & Molecular Biology
Carolina S. Ilkow, Monique Marguerie, Cory Batenchuk, Justin Mayer, Daniela Ben Neriah, Sophie Cousineau, Theresa Falls, Victoria A. Jennings, Meaghan Boileau, David Bellamy, Donald Bastin, Christiano Tanese de Souza, Almohanad Alkayyal, Jiqing Zhang, Fabrice Le Boeuf, Rozanne Arulanandam, Lawton Stubbert, Padma Sampath, Steve H. Thorne, Piriya Paramanthan, Avijit Chatterjee, Robert M. Strieter, Marie Burdick, Christina L. Addison, David F. Stojdl, Harold L. Atkins, Rebecca C. Auer, Jean-Simon Diallo, Brian D. Lichty, John C. Bell
Article
Multidisciplinary Sciences
Rozanne Arulanandam, Cory Batenchuk, Oliver Varette, Chadi Zakaria, Vanessa Garcia, Nicole E. Forbes, Colin Davis, Ramya Krishnan, Raunak Karmacharya, Julie Cox, Anisha Sinha, Andrew Babawy, Katherine Waite, Erica Weinstein, Theresa Falls, Andrew Chen, Jeff Hamill, Naomi De Silva, David P. Conrad, Harold Atkins, Kenneth Garson, Carolina Ilkow, Mads Kaern, Barbara Vanderhyden, Nahum Sonenberg, Tommy Alain, Fabrice Le Boeuf, John C. Bell, Jean-Simon Diallo
NATURE COMMUNICATIONS
(2015)
Article
Biochemistry & Molecular Biology
Marie-Eve Wedge, Erika Sayuri Naruzawa, Martha Nigg, Louis Bernier
CANADIAN JOURNAL OF MICROBIOLOGY
(2016)
Article
Oncology
Laura Evgin, Carolina S. Ilkow, Marie-Claude Bourgeois-Daigneault, Christiano Tanese de Souza, Lawton Stubbert, Michael S. Huh, Victoria A. Jennings, Monique Marguerie, Sergio A. Acuna, Brian A. Keller, Charles Lefebvre, Theresa Falls, Fabrice Le Boeuf, Rebecca A. Auer, John D. Lambris, J. Andrea McCart, David F. Stojdl, John C. Bell
MOLECULAR THERAPY-ONCOLYTICS
(2016)
Article
Cell Biology
Mohammed Selman, Paula Ou, Christopher Rousso, Anabel Bergeron, Ramya Krishnan, Larissa Pikor, Andrew Chen, Brian A. Keller, Carolina Ilkow, John C. Bell, Jean-Simon Diallo
SCIENCE TRANSLATIONAL MEDICINE
(2018)
Article
Oncology
Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell, Carolina S. Ilkow
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2018)
Article
Biotechnology & Applied Microbiology
Jiqing Zhang, Lee-Hwa Tai, Carolina S. Ilkow, Almohanad A. Alkayyal, Abhirami A. Ananth, Christiano Tanese de Souza, Jiahu Wang, Shalini Sahi, Lundi Ly, Charles Lefebvre, Theresa J. Falls, Kyle B. Stephenson, Ahmad B. Mahmoud, Andrew P. Makrigiannis, Brian D. Lichty, John C. Bell, David F. Stojdl, Rebecca C. Auer
Article
Oncology
Brian A. Keller, Brian J. Laight, Oliver Varette, Aron Broom, Marie-Eve Wedge, Benjamin McSweeney, Catia Cemeus, Julia Petryk, Bryan Lo, Bruce Burns, Carolyn Nessim, Michael Ong, Roberto A. Chica, Harold L. Atkins, Jean-Simon Diallo, Carolina S. Ilkow, John C. Bell
Summary: Mutations in BRAF are common in melanoma and other cancers, but treating patients with mutant BRAF(K601N) melanoma remains a challenge. This study developed and characterized a patient-derived BRAF(K601N) melanoma model, showing promising results with MEK inhibition. The model serves as a platform for personalized oncology in rare or treatment-refractory cancers.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Marie-Eve Wedge, Victoria A. Jennings, Mathieu J. F. Crupi, Joanna Poutou, Taylor Jamieson, Adrian Pelin, Giuseppe Pugliese, Christiano Tanese de Souza, Julia Petryk, Brian J. Laight, Meaghan Boileau, Zaid Taha, Nouf Alluqmani, Hayley E. McKay, Larissa Pikor, Sarwat Tahsin Khan, Taha Azad, Reza Rezaei, Bradley Austin, Xiaohong He, David Mansfield, Elaine Rose, Emily E. F. Brown, Natalie Crawford, Almohanad Alkayyal, Abera Surendran, Ragunath Singaravelu, Dominic G. Roy, Gemma Migneco, Benjamin McSweeney, Mary Lynn Cottee, Egon J. Jacobus, Brian A. Keller, Takafumi N. Yamaguchi, Paul C. Boutros, Michele Geoffrion, Katey J. Rayner, Avijit Chatterjee, Rebecca C. Auer, Jean-Simon Diallo, Derrick Gibbings, Benjamin R. tenOever, Alan Melcher, John C. Bell, Carolina S. Ilkow
Summary: This study identifies an artificial microRNA (amiR-4) that enhances the anticancer potency of oncolytic viruses and promotes bystander killing of uninfected cancer cells through the intercellular transfer of extracellular vesicles. These findings suggest that oncolytic viruses can serve as replicating vehicles for amiRNA therapeutics, potentially in combination with other treatment modalities.
NATURE COMMUNICATIONS
(2022)
Review
Biotechnology & Applied Microbiology
Boaz Wong, Rayanna Birtch, Reza Rezaei, Taylor Jamieson, Mathieu J. F. Crupi, Jean-Simon Diallo, Carolina S. Ilkow
Summary: In recent years, there has been significant progress in the use of viral vector-based gene therapy for RNA interference (RNAi) delivery, particularly in the treatment of neurological diseases. However, the application of this technology for cancer treatment still faces challenges. This review discusses the most promising viral vector delivery tools for RNAi therapeutics in cancer treatment and explores strategies to optimize their safety and efficacy.
Review
Nanoscience & Nanotechnology
Taha Azad, Helena J. Janse J. van Rensburg, Jessica Morgan, Reza Rezaei, Mathieu J. F. Crupi, Rui Chen, Mina Ghahremani, Monire Jamalkhah, Nicole Forbes, Carolina Ilkow, John C. C. Bell
Summary: Luciferase-based biosensors have wide applications in virology, being used to study virus structure and function, as well as successfully identifying viral inhibitors. These biosensors are playing a critical role in researching SARS-CoV-2 and developing serological assays and drugs during the COVID-19 pandemic.
ACS NANOSCIENCE AU
(2021)
